hydroxyurea has been researched along with Adverse Drug Event in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 9.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
| "Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)." | 6.73 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008) |
| "The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 5.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
| "Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea." | 2.77 | Impact of hydroxyurea on clinical events in the BABY HUG trial. ( Alvarez, O; Files, BA; Iyer, R; Kalpatthi, R; Lebensburger, J; Luo, Z; Miller, ST; Seaman, P; Thompson, B; Thornburg, CD; Wang, WC; Ware, RE, 2012) |
| "Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)." | 2.73 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008) |
| " We did not observe any significant adverse effects during the treatment period." | 1.91 | Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India. ( Chandak, GR; Lad, H; Nahrel, R; Naskar, S; Patra, PK; Punyasri Pasupuleti, SKDB; Sihare, P, 2023) |
| "Hydroxyurea has proven beneficial in the treatment of SCD and prevention of disease-related complications." | 1.43 | Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know. ( Rees, AL, 2016) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Lad, H | 1 |
| Naskar, S | 1 |
| Punyasri Pasupuleti, SKDB | 1 |
| Nahrel, R | 1 |
| Sihare, P | 1 |
| Chandak, GR | 1 |
| Patra, PK | 1 |
| Curto-Garcia, N | 1 |
| Harrison, CN | 1 |
| Verstovsek, S | 1 |
| Passamonti, F | 1 |
| Rambaldi, A | 1 |
| Barosi, G | 1 |
| Rosen, PJ | 1 |
| Rumi, E | 1 |
| Gattoni, E | 1 |
| Pieri, L | 1 |
| Guglielmelli, P | 1 |
| Elena, C | 1 |
| He, S | 1 |
| Contel, N | 1 |
| Mookerjee, B | 1 |
| Sandor, V | 1 |
| Cazzola, M | 1 |
| Kantarjian, HM | 1 |
| Barbui, T | 1 |
| Vannucchi, AM | 1 |
| Rees, AL | 1 |
| Nand, S | 1 |
| Godwin, J | 1 |
| Smith, S | 1 |
| Barton, K | 1 |
| Michaelis, L | 1 |
| Alkan, S | 1 |
| Veerappan, R | 1 |
| Rychlik, K | 1 |
| Germano, E | 1 |
| Stiff, P | 1 |
| Scott, JP | 1 |
| Thornburg, CD | 1 |
| Files, BA | 1 |
| Luo, Z | 1 |
| Miller, ST | 1 |
| Kalpatthi, R | 1 |
| Iyer, R | 1 |
| Seaman, P | 1 |
| Lebensburger, J | 1 |
| Alvarez, O | 1 |
| Thompson, B | 1 |
| Ware, RE | 1 |
| Wang, WC | 1 |
| Lori, F | 1 |
| Pollard, RB | 1 |
| Whitman, L | 1 |
| Bakare, N | 1 |
| Blick, G | 1 |
| Shalit, P | 1 |
| Foli, A | 1 |
| Peterson, D | 1 |
| Tennenberg, A | 1 |
| Schrader, S | 1 |
| Rashbaum, B | 1 |
| Farthing, C | 1 |
| Herman, D | 1 |
| Norris, D | 1 |
| Greiger, P | 1 |
| Frank, I | 1 |
| Groff, A | 1 |
| Lova, L | 1 |
| Asmuth, D | 1 |
| Lisziewicz, J | 1 |
| Jusko, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118] | 82 participants (Actual) | Observational | 2015-12-31 | Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion) | |||
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
4 trials available for hydroxyurea and Adverse Drug Event
| Article | Year |
|---|---|
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Contraindications; Drug-Related Side Effects and Adverse Rea | 2014 |
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2008 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Drug-Re | 2005 |
9 other studies available for hydroxyurea and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Child; Drug-Related Side Effects and Adverse Reactions; Fetal | 2023 |
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.
Topics: Aged; Animals; Blood Cell Count; Clinical Trials, Phase III as Topic; Disease Models, Animal; Diseas | 2018 |
Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug-Related Side Eff | 2016 |
Hydroxurea and sickle cell disease: Its been a long, long time coming.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug-Rel | 2010 |
Pharmacodynamic principles in chemical teratology: dose-effect relationships.
Topics: Abnormalities, Drug-Induced; Adsorption; Cyclophosphamide; Dose-Response Relationship, Drug; Drug-Re | 1972 |